Disclaimer: This article has been retracted by the publisher. The following summary describes the original research claims, but the scientific validity of these findings is currently disputed.
Introduction
Chronic wounds, particularly diabetic foot ulcers, represent a significant clinical challenge due to persistent infections by multidrug-resistant (MDR) bacteria like Pseudomonas aeruginosa (P.a). These wounds often remain trapped in a prolonged inflammatory phase, exacerbated by a toxic microenvironment characterized by low pH and high protease activity. While Polymyxin B (PMB) is a potent "last-resort" antibiotic against MDR bacteria, its systemic toxicity limits its clinical utility. This study proposed a "smart" hydrogel system designed for localized, responsive delivery of PMB and anti-inflammatory agents to accelerate healing.
Hydrogel Design and Synthesis
The researchers developed a dual-responsive hydrogel, GelMA/OSSA/PMB, composed of three functional building blocks:
- Gelatin methacryloyl (GelMA): Provides a biocompatible scaffold that degrades in response to proteases.
- Oxidized sulfated sodium alginate (OSSA): A modified polysaccharide that serves as an anti-inflammatory agent.
- Polymyxin B (PMB): The antimicrobial payload.
The synthesis involved chemically anchoring PMB to OSSA via a pH-sensitive Schiff’s base reaction. This complex was then integrated into a GelMA matrix and crosslinked using blue light. This design ensures that PMB is released primarily in the acidic environment of an infected wound, while the degradation of GelMA by local enzymes facilitates the release of OSSA to manage inflammation.
Mechanism of Action: Spatiotemporal Release
The hydrogel operates through a "one-two punch" mechanism:
- Phase 1: Anti-infection. In the presence of infection (low pH), the Schiff’s base bonds break, releasing PMB to eradicate MDR bacteria and inhibit biofilm formation.
- Phase 2: Anti-inflammation. As the bacterial load decreases and the GelMA matrix degrades, OSSA is released. OSSA acts as a molecular sponge, binding to inflammatory cytokines and reducing oxidative stress, thereby transitioning the wound from the inflammatory phase to the proliferation phase.
Key Findings
- Responsive Release: In vitro studies demonstrated that ~99.9% of PMB was released at pH 5.5, compared to ~82% at pH 7.4, confirming the pH-triggered mechanism.
- Antibacterial Efficacy: The hydrogel achieved a 99% kill rate against MDR P. aeruginosa and effectively prevented biofilm development.
- In Vivo Healing: In a diabetic mouse model, wounds treated with the GelMA/OSSA/PMB hydrogel showed ~27.8% closure by day 7, significantly higher than the control group (0.2%). By day 14, treated wounds exhibited complete healing with organized granulation tissue and hair follicle formation.
- Transcriptomic Insights: RNA-sequencing of wound tissue indicated that the treatment upregulated regenerative pathways (Wnt and TGF-β) and downregulated major inflammatory pathways (NF-κB and TNF).
Conclusion and Retraction Note
The study presented a sophisticated approach to treating chronic wounds by matching drug release to the wound microenvironment. However, readers must note that this article has been retracted. While the chemical principles of pH-responsive Schiff's base reactions and enzyme-degradable hydrogels are well-established in literature, the specific data, images, and quantitative outcomes reported in this paper are no longer considered scientifically reliable by the academic community.
Summary updated